MORRISVILLE, NC – June 26, 2020 – Q2 Solutions, a leading clinical trial laboratory services organization, announced today a global bioanalytical strategic partnership with LGC, a global leader in the Life Science Tools sector. The partnership provides Q2 Solutions’ customers with access to LGC’s bioanalytical facility, one of Europe’s largest dedicated bioanalytical services sites, and it provides LGC’s customers with access to the Q2 Solutions bioanalytical facilities in the US and China.
Q2 Solutions and LGC will each contribute their extensive experience and capabilities in small and large molecule bioanalysis to support a customer-centric approach. Given both organizations’ focus on delivering the highest quality science and services, customers can now enjoy a globally harmonized delivery of bioanalytical testing for their small- and large-molecule development programs.
“With LGC’s comprehensive bioanalytical center in Cambridge, UK, we see a synergistic fit between our organizations,” said Kevin Jones, vice president, general manager, Bioanalytical, ADME, and Vaccines Services, for Q2 Solutions. “This collaboration will offer our clients an expanded suite of bioanalytical capabilities and scientific expertise with an expanded global footprint operating from labs in the US, Europe and China.”
“Over the last couple of years LGC has had a very positive experience collaborating together with Q2 Solutions on behalf of mutual clients”, said Michael van der Merwe, commercial director at LGC. “This reinforced the strategic, operational and cultural fit between our organisations and the decision to establish this partnership. We are looking forward to working with Q2 Solutions and deploying this global offering.”
About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. As one of the largest bioanalytical and ADME service providers in the world, Q2 Solutions excels at large-scale screening using in-house or client-customized protocols with rapid turnaround. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.
LGC is a global leader in the Life Science Tools sector, which serves customers across a number of end markets, including human healthcare, agri-food & the environment. LGC provides a comprehensive range of measurement tools, proficiency testing schemes, supply chain assurance standards and specialty genomics reagents underpinned by leading analytical and measurement science capabilities.
With 20+ years working to GLP and GCP in one of the world’s most extensive bioanalytical facilities, LGC’s Drug Development Solutions team are dedicated to providing on time, high quality data to help make critical decisions on the safety and efficacy of small and large molecules in drug development.
LGC’s Cambridge, UK facility is home to Centres of Excellence for Immunogenicity and Protein LC-MS. Supported by the latest mass spectrometry and immunochemistry technologies, the team have developed in-depth expertise in these key areas of bioanalytical science with successful contributions to biopharmaceutical research.